The Chicago Entrepreneur

Viking Therapeutics’ stock boosted by positive data from trial of treatment for rare metabolic disorder X-ALD

Viking, which is also developing a weight-loss pill, has a buy rating from all 13 analysts offering coverage.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post The U.S. fertility rate is falling. Is there anything we can do?
Next post Wall Street’s most bearish firm on stocks says there’s a chance of an upswing